A preliminary cervical cancer screening cascade for eight provinces rural Chinese women: a descriptive analysis of cervical cancer screening cases in a 3-stage framework

Shu-Xia Wang1, Jiu-Ling Wu1, Rui-Min Zheng1, Wei-Yi Xiong2, Jing-Yi Chen3, Lan Ma1, Xiao-Min Luo1

1Department of Women’s Health, National Center for Women and Children’s Health, Chinese Center for Disease Control and Prevention, Beijing 100081, China; 2Center of Drug Reevaluation, National Medical Products Administration, Beijing 100044, China; 3Center for Project Supervision and Management, National Health Commission of China, Beijing 100044, China.

Abstract
Background: Cascade analysis is an effective method to analyze the processing data of an event, such as a provided service or a series of examinations. This study aimed to develop a primary cervical cancer screening cascade in China to promote the quality of the screening process.

Methods: We designed a cervical cancer screening cascade in China according to the program flow chart. It had three stages, each with two steps and one result. Data from 117,522 women aged 35 to 64 years in the Rural Cervical Cancer Surveillance Project from January 1, 2014, to December 31, 2014, were collected to analyze the main results of the cascade. The data and proportion are used to describe the follow-up of cervical cancer and pre-cancer detection rate.

Results: In 2014, 117,522 (80.94% of all cases reported by the Rural Cervical Cancer Surveillance Project) women aged 35 to 64 years had not received cervical cytology in the previous 3 years. The pre-cancer and cancer detection rates were 256.12/100,000 and 16.16/100,000, respectively. A total of 3031 cases failed to follow-up through the screening process, and 1189, 1555, and 287 cases were lost at cervical cytology, colposcopy, and histopathological screening stages, respectively. The estimated cases of pre-cancer and cancer would have been 544 and 34, respectively, and the estimated detection rates of pre-cancer and cancer would have been 462.89/100,000 and 28.93/100,000, respectively.

Conclusion: In order to increase the detection rate of cervical cancer, cervical cancer screening staff should focus on increasing the rate of follow-up of those who are positive for cervical cancer screening (ie, those with positive cytology results), especially for the 40 to 44 years age range.

Keywords: Uterine cervical neoplasms; Mass screening; China

Introduction
Cervical cancer is the fourth highest incident cancer in the world and a leading cause of cancer death, especially in developing countries. In 2012, 528,000 new cervical cancer cases were diagnosed worldwide, 85% of which occurred in less-developed regions. Each year, 266,000 women die of cervical cancer, most (90%) in low- to middle-income countries.1,2 China has a relatively high cervical cancer disease burden. According to the National Cancer Institute of China, in 2011, there were 87,982 new cervical cancer cases and 23,375 cancer deaths in 2011.[1,2]

There is compelling evidence that cervical cancer is one of the most preventable and treatable forms of cancer if detected early and managed effectively.[3,4] Cervical cancer screening is the most effective intervention for early detection and prevention of the disease.[5] Research on the economic burden of cervical cancer has shown that screening can reduce both the medical resources required and the economic costs associated with the disease.[6] A study by Zhao et al[7] found that all screening strategies decrease cervical cancer mortality and effectively increase lifespans.

According to the Comprehensive Cervical Cancer Control guideline edited by the World Health Organization (WHO), national cervical cancer prevention and control programs should be implemented in accordance with the WHO framework, which describes six components or building blocks that constitute a strong health care system.[8] In China, the National Rural Cervical Cancer Screening Project, supported by the National Health and Family Planning Commission of the People’s Republic of China,
has been operating nationwide since 2009. By the end of 2014, nearly 43 million rural women had received cervical cancer screening, this number, 60,057 cervical pre-cancer and cancer cases were detected. Early-stage cervical cancer was detected in 90% of the women diagnosed.

This project has been welcomed in the target areas and has led to some socioeconomic benefits. However, during the field research in some areas, some women who should have attended for screening did not, and missing data during the reporting process biased the project’s final analysis. There is a gap between the actual detection rate and the estimated detection rate during the cervical cancer screening process. This gap is caused by the missing data during screening and weakens the effect of the screening.

Cascade analysis is an effective method to analyze the processing of data from an event, such as a provided service or a series of examinations. Gimbel et al. established the following prevention of mother-to-child transmission (pMTCT) cascade. Gimbel et al. established a pMTCT cascade analysis tool to support health facility managers to assess facility performance. Based on a comprehensive review and meta-analysis, Zeng et al. mapped out a pMTCT cascade that reflects the continuum of service provisions for both pregnant women and infants born to human immunodeficiency virus-positive mothers since 2003 in China.

The study aimed to develop a primary cervical cancer screening cascade in China based on the cervical cancer screening process and to describe the gap between the actual and estimated cervical cancer and pre-cancer detection rates in 2014 in the surveillance regions.

Methods

Ethical approval

This study was approved by the National Center for Women and Children’s Health, Chinese Center for Disease Control and Prevention Ethical Review Committee (No. FY2016-009), and all participants provided written informed consent.

The cervical cancer screening cascade

The process of cervical cancer screening comprises three steps established in 2015 by the NCWCH (Figure 1). In the present study, the first step involved cervical cytology screening using the Traian Bethesda system (TBS) for classification and reporting. Women who had a positive result in the cytology examination received a colposcopy examination. Women who had a positive colposcopy result received a histopathological examination. As the human papillomavirus test was not used until 2015, it was excluded from this study. Pre-cancer includes cervical intra-epithelial neoplasia 2 and cervical intra-epithelial neoplasia 3. The abnormal and suspected cases in the cervical cancer screening included atypical squamous cells (ASC) of undetermined significance or above in the cervical cytology examination, abnormal, and suspected results in the colposcopy examination, and high-grade squamous intra-epithelial lesion or above in the histopathological examination.

We designed the cervical cancer screening cascade according to the program flow chart. The cascade has three stages, each of which contains two steps and one result (Table 1).

The cascade result comprises four parts:

(1) Number and rate of follow-up cases in steps 1 to 6 and results 1 to 3.
(2) Number and rate of lost cases in steps 1 to 6.
(3) Number and rate of cervical cancer and pre-cancer cases of missed screening and reporting at each step.
(4) Estimated cancer and pre-cancer detection rate.

From the cascade, we established the assumption that the rates of positive cervical cytology, colposcopy, and histopathology results in the lost cases at each stage are identical to the actual detection situation. Therefore, we could calculate the estimated number and rate of lost cases of pre-cancer and cancer to obtain a full picture of the number of pre-cancer and cancer cases in all women receiving screening as well as the extent of lost pre-cancer and cancer cases.

Data sources

According to the administrative district division and the implementation of cervical cancer screening, two to three provinces were randomly selected from eastern, western and internal areas of China, respectively, and two counties were randomly selected from each province as survey areas. A total of 16 counties from eight provinces (Hebei, Liaoning, Hubei, Hunan, Guangdong, Guizhou, Yunnan, and Shaanxi) were included in the study.

Women aged 35 to 64 years from the above rural areas volunteered for cervical cancer screening from January 1, 2014 to December 31, 2014. Women who had duplicate records in the system were excluded from the study. The following demographic characteristics and clinical data were collected, including medical history, gynecological examinations, cervical cytology examinations, colposcopy examinations, and histopathological examinations. The study outcomes were number and proportion of cervical cancer and pre-cancer cases.

All data in this study were collected in the National Rural Cervical Cancer Screening Project using an electronic system established in 2013. This real-time data-monitoring and error-correction system collects case-based data from all women who had received cervical cancer screening in the surveillance regions. In addition to the number of women screened and diagnosed, the system also collects processing data such as cytology, colposcopy, and histopathological examinations results. The system is equipped with quality control measures, such as logical verification. Data verification was carried out monthly and quarterly.
Statistical analysis
All data were exported from the data collection system and imported into SPSS 13.0 (SPSS, Chicago, IL, USA) for statistical description and analysis. The socio-demographic data are described using the mean and standard deviation (SD) or median for continuous variables and frequencies (%) for categorical variables. The data describe the total loss to follow-up, the number of lost patients with positive cytology results, the actual number of cases of pre-cancer and cancer detected, the estimated number of lost patients with pre-cancer and cancer, and the estimated number of cases of pre-cancer and cancer detected. The proportions describe the crude loss rate (%), the loss rates of positive cytology results (%), the actual detection rates of pre-cancer and cancer (100,000), the estimated loss rates of pre-cancer and cancer (100,000), the estimated detection rates of pre-cancer and cancer (100,000), and the estimated loss numbers/estimated detection numbers of pre-cancer and cancer cases. As a person is a whole part, the result of the calculation took the integer part.

Results

General data
In this study, 145,194 cases were reported by the National Rural Cervical Cancer Surveillance Project, 117,522
Numbers and rates of patient follow-ups in steps 1 to 6 and results 1 to 3

Cervical cytology results were reported for all 117,522 patients (100.00%) in this study, and TBS classification results were reported for 116,333 (98.99%). Overall, 4830 (4.15%) patients had results that were above ASC or atypical glandular cells requiring colposcopy, and 3407 (70.54%) received this procedure. The results of colposcopy examinations were reported for 3275 patients (96.13%), and 1631 (49.80%) had abnormal colposcopy results necessitating further histopathological examination. The results of histopathological exams were reported for 1344 patients (82.40%); 301 (22.40%) were pre-cancer and 19 (1.41%) were cancer requiring further treatment [Figure 2]. Therefore, the pre-cancer and cancer detection rates were 256.12/100,000 and 16.16/100,000, respectively.

Women who received cervical cancer screening were divided into six age groups: 35 to 39, 40 to 44, 45 to 49, 50 to 54, 55 to 59, and 60 to 64 years. According to the established cervical cancer screening cascade, we calculated the number and proportion in each step and result [Table 2].

Number and rate of missing cases in steps 1 to 6

According to the cervical cancer screening data analysis, 3031 patients failed to follow-up on the whole screening process, and 1189, 1555, and 287 patients were lost at the cervical cytology, colposcopy, and histopathological screening stages, respectively. In addition, we computed the number lost to follow-up in the groups aged 35 to 39, 40 to 44, 45 to 49, 50 to 54, 55 to 59, and 60 to 64 years [Table 3 and Figure 3].

Estimated cancer and pre-cancer detection rate

The numbers of women with pre-cancer or cancer, respectively, who did not receive examinations or whose results were not reported were 243 and 15. If there had been no failures of examination and reporting in the course of the screenings, the estimated cases of pre-cancer and cancer would have been 544 and 34, respectively, and the estimated detection rates of pre-cancer and cancer would have been 462.89/100,000 and 28.93/100,000, respectively.

Discussion

There is a gap between the estimated and the actual detection rates in the cervical cancer screening process. Some possible causes of this are poor technical abilities of local health care workers, missing data, diagnostic errors, and sub-standard quality control and data checks at each level. In this study, we focused on the failure to follow-up and report data during the screening process.

The detection rate of pre-cancer and cancer

The actual cervical cancer detection rate was 16.16/100,000 in 2014 according to the National Rural Cervical Cancer Surveillance Project. According to GLOBOCAN2012, the estimated crude incidence of cervical cancer in China was 9.4/100,000,[11] which is much lower than our study findings. The estimated crude incidence worldwide, in more-developed regions, and in

Table 1: The preliminary cervical cancer screening cascade in rural Chinese women.

| Stages                  | Steps           | Indexes                                                                 |
|-------------------------|-----------------|-------------------------------------------------------------------------|
| Stage 1: cervical cytology | Step 1         | Number of cases receiving cervical cytology                            |
|                         | Step 2         | Number/proportion of cases with reported cervical cytology result      |
| Result 1                |                 |                                                                         |
| Stage 2: colposcopy     | Step 3         | Number/proportion of cases who should receive colposcopy examination   |
| Result 2                | Step 4         | Number/proportion of cases receiving colposcopy examination            |
| Stage 3: histopathological | Step 5       | Number/proportion of cases receiving a histopathological examination  |
| Result 3                | Step 6         | Number/proportion of cases with reported histopathological examination result |
|                         |                 | Number/proportion of cases who had pre-cancer and cancer               |
less-developed regions was 15.1/100,000, 13.0/100,000, and 15.6/100,000, respectively. The results of our study of rural women receiving cervical screening are similar to findings from less-developed regions. The prevalence of cervical cancer reported in the China Health Statistical Yearbook was 13.3/100,000 in 2012, a figure lower than reported here.

The actual cervical pre-cancer detection rate was 256.12/100,000 in 2014. According to data from the National Rural Cervical Cancer Screening Project, the cervical pre-cancer detection rates were 106.85/100,000 in 2012 and 119.26/100,000 in 2013, much lower than reported here. The substantial differences in pre-cancer detection rates between 2013 and 2014 may be because the 2013 results were based on aggregate data, whereas the 2014 results were based on individual participants, and are thus more reliable.

There were differences in the estimated and actual detection rates of cervical cancer as a result of the failure to follow-up in every step. Assuming that cervical cancer and pre-cancer detection rates for women lost to follow-up were approximately equal to rates for women who were followed-up, 578 cases of cervical cancer and pre-cancer should have been detected, of which 258 cases of cancer and pre-cancer were lost to follow-up. That is, almost 44.64% of cancers and pre-cancers were not detected because of patient failure to follow-up with colposcopy and histopathological examinations. In addition, 169 of 258 (65.50%) cases of cancer and pre-cancer were not detected because of failure to follow-up with a colposcopy (step 3).

### Table 2: The stages and results of cervical cancer screening cascade among different age of Chinese rural women in 2014.

| Stages         | Steps | Total population | Age (years) |
|----------------|-------|------------------|-------------|
|                |       |                  | 35–39       | 40–44       | 45–49       | 50–54       | 55–59       | 60–64       |
| Stage 1: cervical cytology | Step 1 | 117,522 |               | 17,178      | 23,266      | 25,632      | 22,923      | 15,352      | 12,315      |
|                | Step 2 | 116,333 (98.99) | 16,991 (98.91) | 23,012 (98.91) | 25,363 (98.95) | 22,700 (99.03) | 15,952 (99.20) | 12,315 (98.97) |
|                | Step 3 | 4830 (4.15) | 628 (3.70) | 923 (4.01) | 1145 (4.51) | 998 (4.40) | 664 (4.16) | 472 (3.83) |
| Result 1       |       |                  | Result 2    | 1344 (82.40) | 287 (17.60) | 219 (86.90) | 321 (82.31) | 340 (83.95) | 365 (82.40) |
| Stage 2: colposcopy | Step 4 | 3407 (70.54) | 649 (75.19) | 807 (70.48) | 689 (69.04) | 444 (66.87) | 314 (66.53) | 299 (66.82) | 291 (66.82) |
|                | Step 5 | 451 (98.26) | 675 (97.26) | 782 (96.90) | 657 (93.36) | 419 (94.37) | 291 (92.68) | 107 (36.77) | 74 (69.16) |
| Result 3       |       |                  | Result 2    | 1344 (100.00) | 219 (100.00) | 321 (100.00) | 340 (100.00) | 266 (100.00) | 124 (100.00) | 74 (100.00) |
| Stage 3: histopathological | Step 6 | 301 (32.40) | 41 (18.72) | 78 (22.94) | 50 (18.80) | 26 (20.97) | 19 (25.68) | 12 (15.38) | 12 (15.38) |

Data are presented as n or n (%).
Losses existed in almost every step of the cervical cancer screening cascade. The most common loss was in step 3, failure to receive a colposcopy. Some 1423 (29.46%) women who should have undergone colposcopies did not. If these colposcopies had been performed, 159 pre-cancers and ten cancers would have been detected, accounting for 65% and 67%, respectively, of the cascade. In addition, 64 pre-cancers and four cancers would have been detected in the women who should have received colposcopies but did not, accounting for 25% and 27% of the cascade.

The key step is the colposcopy; this tends to be ignored, which results in a higher loss rate. Therefore, we should strengthen the follow-up for colposcopy to ensure the procedure is performed after histopathological examination [Figure 2].

The actual detection rate and the estimated detection rate differed across these age groups. The difference between the actual detection rate and the estimated detection rate was greatest in the 40 to 44 years age range, which was characterized by a high detection rate. Therefore, the highest loss ratio and estimated detection rate were for the 40 to 44 years age range.

Many studies have identified possible positive and negative biomarkers for cervical pre-cancer, which could help to identify cancer earlier.[17-19] The biomarkers are more sensitive to increase the early detection rate and reduce the false negative rate. However, the examination of biomarkers is more expensive than screening by cervical cytology, but taking shorter to process. For these reasons, biomarkers are not yet used in nationwide screening and need further research to explore the reasonable framework. Fertility-sparing approaches play an important role in improving the quality of life of women with cervical cancer earlier.[20-22] Therefore, increase the early detection rate and reduce failing in follow-up rate are more important.

In recent years, artificial intelligence is widely used in disease diagnosis and screening, such as cervical cancer screening, which can more effectively enhance follow-up.[23,24] However, studies on the sensitivity and specificity of artificial intelligence should be done in the future.

**Limitations**

The calculations of the estimated cervical cancer and pre-cancer detection rates in this study were based on the assumption that cervical cancer and pre-cancer detection rate in women lost to follow-up was approximately equal to the rates for those who were followed-up. Further research is necessary to assess whether the incidence of cervical cancer was similar between women followed-up and those not followed-up.

The 16 counties included in this study have relatively low economic development compared with other counties in China. Therefore, they may not be representative of the economic situation in urban areas or in the whole country.

---

**Table 3: The key indexes during the cervical cancer screening cascade among Chinese rural women in 2014.**

| Index                                                                 | Total population | 35–39 | 40–44 | 45–49 | 50–54 | 55–59 | 60–64 |
|----------------------------------------------------------------------|-----------------|-------|-------|-------|-------|-------|-------|
| Total number lost to follow-up and crude loss rate                  | 3031 (2.58)     | 397 (2.31) | 571 (2.45) | 697 (2.72) | 610 (2.66) | 414 (2.57) | 342 (2.75) |
| Patients with positive cytology results lost and loss rate          | 1423 (29.46)    | 169 (26.91) | 229 (24.81) | 338 (29.52) | 309 (30.96) | 220 (33.13) | 158 (33.47) |
| Actual detection number of pre-cancer and cancer and actual detection rate (100,000) | 320 (27.29) | 43 (250.32) | 89 (182.53) | 83 (323.81) | 55 (239.93) | 28 (174.13) | 22 (176.81) |
| Estimated lost number of patients with pre-cancer and cancer and estimated loss rate (100,000) | 258 (219.53) | 24 (139.71) | 72 (309.46) | 62 (241.89) | 42 (183.22) | 30 (186.57) | 28 (225.03) |
| Estimated detection number of pre-cancer and cancer and estimated detection rate (100,000) | 578 (491.82) | 67 (390.03) | 161 (692.00) | 145 (565.70) | 97 (432.16) | 58 (360.70) | 50 (401.83) |
| Estimated loss number/estimated detection number of pre-cancer and cancer | 44.64 | 35.82 | 44.72 | 42.76 | 43.30 | 51.72 | 56.00 |

Data are presented as n or n (%).
In conclusion, failure in examination and reporting is common in the course of cervical cancer screening and can be attributed not only to the level of screening skills but also to the quality of follow-up at each step. Loss of follow-up would reduce the detection rate of cervical cancer and precancerous lesions directly. In order to increase the detection rate of cervical cancer, cervical cancer screening staff should focus on increasing the rate of follow-up of those who are positive for cervical cancer screening (ie, those with positive cytology results), especially for an age range of 40 to 44 years.

Conflicts of interest
None.

References
1. International Agency for Research on Cancer (IARC), World Health Organization (WHO). GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012: Cancer Fact Sheets: Cervical Cancer. Available from: http://globocan.iarc.fr/Pages/online.aspx. Accessed May 2, 2017.
2. Chen WQ, Zhang RS, Zeng HM, Zou XN, Zhang SS, He J. Report of cervical cancer incidence and mortality in China, 2011 (in Chinese). China Cancer 2015;24:1–10. doi: 10.11773/jissn.1004-0242.2015.01. A001.
3. Mboumba Bouassa RS, Prauzuck T, Lethu T, Jenabian MA, Meye JF, Bacle L. Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease. Expert Rev Anti Infect Ther 2017;15:613–627. doi: 10.1080/14787210.2017.1322902.
4. Vaccarella S, Franceschi S, Zaridze D, Poljak M, Veenars P, Plummer M, et al. Preventable fractions of cancer of cervical via effective screening in six Baltic, central, and eastern European countries 2017–40: a population-based study. Lancet Oncol 2016;17:1445–1452. doi: 10.1016/s1470-2045(16)30275-3.
5. Vaccarella S, Franceschi S, Bray F. The incremental benefits of implementing effective cervical cancer screening. Int J Cancer 2016;138:254–255. doi: 10.1002/ijc.29700.
6. Larsson DR, Chang YC, Byrd TL, Lee Smith J, Fernandez ME, Wilson KM. Cervical cancer screening with AMIGAS: a cost-effectiveness analysis. Am J Prev Med 2014;46:617–623. doi: 10.1016/j.amepre.2013.08.017.
7. Zhao FH, Chen JF, Gao XC, Gao LM, Liu QG, Liu ZH, et al. Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment. Chinese J Oncol 2012;34:632–636. doi: 10.3760/cma.j.issn.0253-7666.2012.08.017.
8. World Health Organization. Comprehensice Cervical Cancer Control: A Guide Essential Practice (Second Edition) in 2014. Available from: https://www.who.int/reproductivehealth/publications/cancer/cervical-cancer-guide/en/. Accessed May 3, 2017.
9. Wei LJ, Wu J. Guidelines for Quality Assurance and Quality Control of Cervical Cancer Screening. Beijing: People’s Medical Publishing House; 2015: 13.
10. Woolf SH, Kuzel AJ, Dovey SM, Phillips RL Jr. A string of mistakes: preventing medical errors. Ann Fam Med 2004;2:317–326. doi: 10.1370/afm.126.
11. Stringer EM, Chintu N, Creek TL, Etokudje DK, Coetzee D, et al. Monitoring effectiveness of programs to prevent mother–to-child HIV transmission in lower-income countries. Bull World Health Organ 2008;86:57–62. doi: 10.2471/BLT.07.043117.
12. Gimmel S, Voss J, Mercer MA, Zierler B, Gloyd S, Coutinho Mde J, et al. The prevention of mother-to-child transmission of HIV cascade analysis tool: supporting health managers to improve facility-level service delivery. BMC Res Notes 2014;7:743. doi: 10.1186/1756-0500-7-743.
13. Zeng H, Chow EP, Zhao Y, Wang Y, Tang M, Li L, et al. Prevention of mother-to-child HIV transmission cascade in China: a systematic review and meta-analysis. Sex Transm Infect 2016;92:116–123. doi: 10.1111/sextrans-2014-051877.
14. Lihuai Wei, Juiling Wu. Guidelines for Quality Assurance and Quality Control of Cervical Cancer Screening. Beijing: People’s Medical Publishing House; 2015: 10–12.
15. National Health and Family Planning Commission of the People’s Republic of China. Available from: http://www.nhfpcc.gov.cn/htmlfiles/ zwgk/Data2013/index2013.html. Accessed June 3, 2017.
16. Luo XM, Song L, Wu JL, Liu Y, Li JL, Song B, et al. Analysis of the reported data of national rural cervical cancer screening project from 2012 to 2013, China. Chin J Prev Med 2016;50:346–350. doi: 10.3760/cma.j.issn.0253-9624.
17. Nicol AF, de Andrade CV, Gomes SC Jr, Brusadelli MG, Lodin HM, Wells SI, et al. The distribution of novel biomarkers in carcinoma-in-situ, microinvasive, and squamous cell carcinoma of the uterine cervix. Eur J Gynaecol Oncol 2016;37:668–668. doi: 10.12892/egmo.32420.2016.
18. Vitale SG, Valenti G, Rapisarda AMC, Cali I, Marilli I, Zagarrelli M, et al. P16INK4a as a progression regression tumour marker in SIL cervix lesions: our clinical experience. Eur J Gynaecol Oncol 2016;37:685–688. doi: 10.12892/egmo.3470–4017.
19. Valenti G, Vitale SG, Tropea A, Biondi A, Lagana AS. Markers of uterine cervical cancer: a new scenario to guide surgical practice. Updates Surg 2017;69:441–449. doi: 10.1007/s13304-017-0491-3.
20. Lagana AS, La Rosa VL, Rapisarda AM, Platania A, Vitale SG. Psychological impact of fertility preservation techniques in women with gynaecological cancer. Ercancermedicalscience 2017;1:16.d62.
21. Vitale SG, La Rosa VL, Rapisarda AMC, Lagana AS. The importance of fertility preservation counseling in patients with gynecologic cancer. J Reprod Infertil 2017;18:261–263.
22. Vitale ST, Rossetti D, Tropea A, Biondi A, Lagana AS. Fertility sparing surgery for stage IA type I and G2 endometrial cancer in reproductive-aged patients: evidence-based approach and future perspectives. Updates Surg 2017;69:29–34. doi: 10.1007/s13304-017-0419-y.
23. Elayaraja P, Suganthi M. Automatic approach for cervical cancer detection and segmentation using neural network classifier. Asian Pac J Cancer Prev 2018;19:3571–3580. doi: 10.3322/cpajcp.2018.12.3571.
24. Zhao M, Wu A, Song J, Sun X, Dong N. Automatic screening of cervical cells using block image processing. Biomed Eng Online 2016;15:14. doi: 10.1186/s12938-016-0131-z.

How to cite this article: Wang SX, Wu JL, Zheng RM, Xiong WY, Chen JY, Ma L, Luo XM. A preliminary cervical cancer screening cascade for eight provinces rural Chinese women: a descriptive analysis of cervical cancer screening cases in a 3-stage framework. Chin Med J 2019;132:1773–1779. doi: 10.1097/CM9.000000000000353

www.cmj.org